Inclusion Criteria:  Positive diagnostic RT-qPCR or antigen test for SARS-CoV-2 Symptomatic patients with up to 8 days from the onset of symptoms, and asymptomatic cases with up to 5 days of positive test for SARS-CoV-2. Patients who agree to participate in the study by signing the informed consent.  Exclusion Criteria:  Patients with severity criteria defined in the Coronavirus Disease Epidemiological and Laboratory Surveillance Guide (Version 3/11/2020) Pregnant or breastfeeding women Women of childbearing age and without commitment to use contraceptive methods during the study time. Inability to complete the study Current treatment with drugs known to interact with ivermectin Known intolerance to ivermectin, its derivate or any of its excipients. Patients with known Child-Pugh C liver disease Patients with prior ivermectin consumption in the 10 days prior to study entry.